Press coverage about Pain Therapeutics (NASDAQ:PTIE) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pain Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.7215765223299 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research firms have recently commented on PTIE. Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 27th. ValuEngine lowered Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
Pain Therapeutics (NASDAQ:PTIE) traded up $0.02 during trading on Thursday, hitting $4.11. The stock had a trading volume of 23,100 shares, compared to its average volume of 48,900. The company has a market capitalization of $26.98, a price-to-earnings ratio of -2.19 and a beta of 2.11. Pain Therapeutics has a twelve month low of $3.10 and a twelve month high of $9.31.
Pain Therapeutics Company Profile
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.